Zacks cuts Gilead Sciences stock to Hold rating

Published on 10/02/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 7.80 billion, up 10.60 percent year over year. Gilead Sciences stock costs EUR 131.25 versus EUR 131.59 on October 2, 2026.

Bauhaus-Poster BIOTECH mit geometrischen Formen und Primärfarben für Gilead Sciences — Gilead Sciences Bauhaus-Poster ISIN US3755581036 geometrisch BIOTECH Primärfarben Konstruktivismus medizinisches Kreuz Design, Illustration mit AI erstellt.

Gilead Sciences (ISIN US3755581036) was downgraded from strong buy to hold by Zacks Research, as MarketBeat reported on October 1, 2026. Gilead Sciences stock was trading at EUR 131.25 at Lang & Schwarz on October 2, 2026 at 3:31 p.m. CEST, down 0.26 percent versus the EUR 131.59 prior close.

Analyst caution follows strong quarter

MarketBeat said Gilead reported USD 7.80 billion in quarterly revenue for the latest reported quarter, up 10.60 percent from the same quarter a year earlier and ahead of the USD 7.40 billion consensus estimate. The company reported adjusted earnings per share of minus USD 6.75, beating the minus USD 7.25 consensus by USD 0.50.

The earnings comparison is mixed rather than uniformly weak. Revenue exceeded expectations by USD 0.40 billion, while the reported loss reflected acquisition-related costs cited in coverage of the quarter.

Guidance points to HIV growth

Gilead raised its full-year 2026 total product sales guidance to USD 30.10 billion to USD 30.40 billion, according to TradingView coverage published October 2, 2026. The same report said Biktarvy sales reached USD 3.80 billion and prophylactic medicine revenue exceeded USD 1.00 billion in the latest quarter.

That guidance gives the downgrade a clear counterweight. The operating story rests on HIV products, while acquisition costs, drug pricing and regulatory pressure remain the factors that can keep earnings below the strength of product sales.

Stock stays below yearly high

Gilead Sciences trades on Nasdaq under ticker GILD in USD. Its primary-exchange quote was last at USD 147.37 on October 2, 2026 at 9:34 a.m. EDT, while the 52-week range stood at USD 109.66 to USD 157.29. The market capitalization was USD 182.7 billion as of October 2, 2026.

MarketBeat's analyst overview lists 23 Buy ratings and six Hold ratings among 29 analysts, with an average twelve-month target of USD 158.78. The target is 7.74 percent above the USD 147.37 primary-exchange quote, making the consensus more constructive than the latest Zacks rating.

Next report is scheduled for October 28

Gilead Sciences is scheduled to report its next earnings on October 28, 2026, according to AltIndex. The date gives investors a defined checkpoint for testing whether the raised sales outlook is translating into stronger earnings after the latest quarterly loss.

At Lang & Schwarz, Gilead Sciences stock was trading at EUR 131.25 on October 2, 2026 at 3:31 p.m. CEST, down 0.26 percent versus the EUR 131.59 prior close of October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.